Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 11:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 32,722 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo Oral Tablet Clear all
Completed Phase 3 Interventional Results available

Reducing Involuntary Movements in Participants With Tardive Dyskinesia

NCT02198794
View directory record Official record
Conditions
Tardive Dyskinesia
Interventions
SD-809, Placebo
Drug
Lead sponsor
Auspex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
44
States / cities
Tuscaloosa, Alabama • Anaheim, California • Glendale, California + 36 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2022 · Synced Oct 2, 2026, 11:22 AM EDT
Completed Phase 2 Interventional Results available

Energy Metabolism in Thyroidectomized Patients

NCT04782856
View directory record Official record
Conditions
Thyroid Goiter, Hypothyroidism, Thyroid Cancer
Interventions
Levothyroxine, Liothyronine, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 89 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 14, 2024 · Synced Oct 2, 2026, 11:22 AM EDT
Terminated Phase 3 Interventional

Single-Dose Cross-Over Study of the Effects of Albuterol-HFA in Exercise Induced Bronchoconstriction

NCT00634829
View directory record Official record
Conditions
Asthma, Bronchospasm
Interventions
albuterol (Armstrong Albuterol HFA), Albuterol Sulfate (Provenetil-HFA), Placebo-HFA
Drug
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
3
States / cities
Denver, Colorado • Englewood, Colorado • Lakewood, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 15, 2013 · Synced Oct 2, 2026, 11:22 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Treatment for a Form of Age-Related Central Auditory Processing Disorder Consisting of Clemastine Fumarate Plus Engineered Sound

NCT07304024
View directory record Official record
Conditions
Central Auditory Processing Disorder, Hearing Impaired (Partially), Hearing, Hearing Abnormality, Hearing Disability, Hearing Disorder, Hearing Disorders, Hearing Impairment, Sensorineural, Hearing Handicap, Hearing Impaired, Hearing Impairment, Hearing Loss, Central Auditory Disease, Noise Exposure, Noise Induced Hearing Loss, Noise-Induced Hearing Loss, Sound Perception, Myelin Degeneration, Myelinopathy, Myelin Integrity, Remyelination, Hidden Hearing Loss, Cocktail Party Skill, Cocktail Party Syndrome, CAPD, Age Problem
Interventions
Clemastine Fumarate Combined With Engineered Sound, Clemastine Fumarate Combined With Pink Noise, Placebo Drug With Engineered Sound, Placebo - Placebo
Combination Product · Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
45 Years to 65 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 2, 2026, 11:22 AM EDT
Completed Phase 4 Interventional Results available

Dutasteride Treatment for the Reduction of Heavy Drinking in Men

NCT01758523
View directory record Official record
Conditions
Alcoholism, Alcohol Abuse, Alcohol Dependence
Interventions
Dutasteride, sugar pill
Drug
Lead sponsor
UConn Health
Other
Eligibility
18 Years to 70 Years · Male only
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 26, 2019 · Synced Oct 2, 2026, 11:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability and Effects of MEDI-563 in Adults With Asthma

NCT00659659
View directory record Official record
Conditions
Asthma
Interventions
MEDI-563, Placebo Comp., Placebo
Drug · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
6
States / cities
Denver, Colorado • Pittsburgh, Pennsylvania • Galveston, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2012 · Synced Oct 2, 2026, 11:22 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

IV Acetaminophen for Postoperative Pain Analgesia After Laparoscopic Hysterectomy

NCT02400580
View directory record Official record
Conditions
Pain
Interventions
IV acetaminophen, placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
183 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 13, 2018 · Synced Oct 2, 2026, 11:22 AM EDT
Recruiting Phase 3 Interventional

Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

NCT07179380
View directory record Official record
Conditions
Pulmonary Hypertension, Interstitial Lung Disease
Interventions
Treprostinil Palmitil Inhalation Powder, Placebo
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years and older
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
18
States / cities
Phoenix, Arizona • Fresno, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 2, 2026, 11:22 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Golimumab in Patients With Active Psoriatic Arthritis

NCT00265096
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
golimumab, Placebo; golimumab
Biological
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
18
States / cities
Huntsville, Alabama • La Jolla, California • Upland, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2013 · Synced Oct 2, 2026, 11:22 AM EDT
Withdrawn Phase 3 Interventional

Randomized Placebo Controlled Trial of IVIg in Glycine Receptor Antibody Positive Stiff-person Syndrome

NCT03749096
View directory record Official record
Conditions
Stiff-Person Syndrome
Interventions
Intravenous Immunoglobulins, Human, Placebos
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 13, 2019 · Synced Oct 2, 2026, 11:22 AM EDT
Completed Phase 4 Interventional Results available

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT03478696
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
budesonide/formoterol, albuterol/salbutamol, FF/UMEC/VI, Placebo to match budesonide/formoterol, tiotropium, Placebo to match FF/UMEC/VI, placebo to match tiotropium, ELLIPTA, MDI, HandiHaler
Drug · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
732 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
42
States / cities
Mobile, Alabama • Bakersfield, California • Sacramento, California + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2020 · Synced Oct 2, 2026, 11:22 AM EDT
Completed Phase 4 Interventional

Combination Therapy in Patients With Depression

NCT00485862
View directory record Official record
Conditions
Depressive Symptoms
Interventions
Atomoxetine Hydrochloride, Sertraline, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 13, 2007 · Synced Oct 2, 2026, 11:22 AM EDT
Completed Phase 3 Interventional Results available

AM-101 in the Treatment of Acute Tinnitus 2

NCT01803646
View directory record Official record
Conditions
Tinnitus
Interventions
AM-101, Placebo
Drug
Lead sponsor
Auris Medical, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 29, 2018 · Synced Oct 2, 2026, 11:22 AM EDT
Not yet recruiting Phase 1 Interventional

Cannabis and Opioid Use Disorder, Study 2

NCT07661446
View directory record Official record
Conditions
Opioid Use Disorders, Cannabis Use
Interventions
Inhaled Cannabis, Intranasal Opioid
Drug
Lead sponsor
University of Kentucky
Other
Eligibility
18 Years to 55 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 2, 2026, 11:22 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma

NCT04850846
View directory record Official record
Conditions
Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma
Interventions
Metformin XR, Placebo
Drug · Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
7
States / cities
Boston, Massachusetts • Brighton, Massachusetts • Methuen, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 2, 2026, 11:22 AM EDT
Recruiting Phase 2 Interventional

Senolytics To slOw Progression of Sepsis (STOP-Sepsis) Trial

NCT05758246
View directory record Official record
Conditions
Sepsis, Acute Infection, Organ Failure
Interventions
Fisetin-dose 1, Fisetin-dose 2, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
65 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
10
States / cities
Gainesville, Florida • Iowa City, Iowa • Burnsville, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 2, 2026, 11:22 AM EDT
Completed Phase 1 Interventional Results available

Dose-Titration and Open-label Extension Study of SRP-4045 in Advanced Stage Duchenne Muscular Dystrophy (DMD) Patients

NCT02530905
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
SRP-4045, Placebo
Drug
Lead sponsor
Sarepta Therapeutics, Inc.
Industry
Eligibility
7 Years to 21 Years · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
3
States / cities
Los Angeles, California • Chicago, Illinois • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 17, 2021 · Synced Oct 2, 2026, 11:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bisphenol A and Muscle Insulin Sensitivity

NCT03771066
View directory record Official record
Conditions
Insulin Sensitivity, Glucose Metabolism Disorders, Microtia
Interventions
bisphenol A, Placebo
Behavioral
Lead sponsor
California Polytechnic State University-San Luis Obispo
Other
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
San Luis Obispo, California
Source: ClinicalTrials.gov public record
Updated Jul 8, 2024 · Synced Oct 2, 2026, 11:22 AM EDT
Recruiting Phase 2Phase 3 Interventional

Efficacy of Buprenorphine and XR-Naltrexone Combination for Relapse Prevention in Opioid Use Disorder

NCT05011266
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Buprenorphine/naloxone, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Rockville, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 2, 2026, 11:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Tafenoquine/Chloroquine DDI Study

NCT00871156
View directory record Official record
Conditions
Malaria
Interventions
Chloroquine, Tafenoquine, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 19, 2017 · Synced Oct 2, 2026, 11:22 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer

NCT01642251
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Carcinoma, Large Cell Lung Carcinoma, Neuroendocrine Carcinoma, Small Cell Carcinoma, Stage IV Non-Small Cell Lung Cancer AJCC v7
Interventions
Cisplatin, Etoposide, Veliparib, Placebo
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
428
States / cities
Loma Linda, California • Palo Alto, California • Aurora, Colorado + 279 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 2, 2026, 11:22 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Clinical Trial of Vitamin D3 to Reduce Cancer Risk in Postmenopausal Women

NCT01052051
View directory record Official record
Conditions
Cancer
Interventions
Vitamin D3, Calcium carbonate
Dietary Supplement
Lead sponsor
Creighton University
Other
Eligibility
55 Years and older · Female only
Enrollment
2,303 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
Fremont, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Oct 2, 2026, 11:22 AM EDT
Completed No phase listed Interventional Accepts healthy volunteers Results available

Efficacy of Arnica Montana in Reducing Postoperative Edema and Pain

NCT03944629
View directory record Official record
Conditions
Arnica, Third Molar Extraction
Interventions
SinEcch, Placebo
Drug · Other
Lead sponsor
Tufts University
Other
Eligibility
18 Years to 40 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 2, 2026, 11:22 AM EDT
Completed Phase 4 Interventional

A Transition Study From Flolan® to Remodulin® in Patients With Pulmonary Arterial Hypertension

NCT00058929
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Pulmonary Hypertension
Interventions
treprostinil sodium
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
8
States / cities
Los Angeles, California • Torrance, California • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2013 · Synced Oct 2, 2026, 11:22 AM EDT